Search results
make important recommendations that include the recognition of high-sensitivity cardiac troponin (hs-cTn) as the preferred biomarker, endorsement of 99th percentile upper reference limits to define myocardial injury, and the use of clinical decision
14 lip 2022 · This primer discusses the use of high-sensitivity cardiac troponin (hs-cTn) testing in context of the 2021 multisociety guidelines for the evaluation and diagnosis of acute chest pain, with a notable focus on analytical aspects of the hs-cTn assays and their implications.
High sensitivity troponin test is more sensitive, & more precise at low concentrations, than standard troponin. High-sensitivity troponin testing allows for faster MI “rule outs” in chest pain patients presenting to the ED. This leads to more efficient ED throughput.
1 lip 2022 · Analytical considerations in deriving 99 th percentile upper reference limits for high-sensitivity cardiac troponin assays: educational recommendations from the IFCC committee on clinical application of cardiac bio-markers [published online June 18, 2022].
High-sensitivity cardiac troponins are the preferred standard for establishing a biomarker diagnosis of acute myocardial infarction, allowing for more accurate detection and exclusion of myocardial injury.
22 lis 2011 · These levels used to be considered indicative of myocardial necrosis. However, with high-sensitivity troponin assays, circulating cTnT or cTnI can be found in the plasma as a result of transient ischemic or inflammatory myocardial injury.
Hs-TnI assays allows for more accurate and precise troponin results at very low levels, which permits for the use of an accelerated chest pain algorithm for rapid rule-out/rule-in of AMI. The new hs-TnI reporting protocol will involve reporting results in ng/L (compared to the previous μg/L).
